Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [Y284] to C Reactive Protein - BSA and Azide free
  • Suitable for: WB, IP, IHC-P
  • Reacts with: Human

Overview

  • Product name

    Anti-C Reactive Protein antibody [Y284] - BSA and Azide free
    See all C Reactive Protein primary antibodies

  • Description

    Rabbit monoclonal [Y284] to C Reactive Protein - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IP, IHC-Pmore details
    Unsuitable for: ICC/IF

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Epitope

    ab32412 reacts with an epitope located in the C terminal region of C Reactive Protein.

  • Positive control

    • IHC-P: Normal human liver tissue. IP: HepG2 whole cell lysate.

  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    ab271830 is the carrier-free version of ab32412. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with

    This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling C Reactive Protein with purified ab32412 at 1/100. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32412).
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skeletal muscle tissue labelling C Reactive Protein with purified ab32412 at 1/100. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32412).
  • Immunoprecipitation - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)
    Immunoprecipitation - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

    ab32412 (purified) at 1/30 immunoprecipitating C Reactive Protein in HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate.

    Lane 1 (input): HepG2 whole cell lysate (10µg)

    Lane 2 (+): ab32412 + HepG2 whole cell lysate.

    Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab32412 in HepG2 whole cell lysate.

    For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM /TBST.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32412).
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded) analysis of human normal liver tissue labelling C Reactive Protein using unpurified ab32412 at a dilution of 1/100.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32412).
  • Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)
    Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-C Reactive Protein antibody [Y284] - BSA and Azide free (ab271830)

Clear all

Recently viewed products

© 2021 Astana Biomed Group LLP. All rights reserved.